Publications by Wim Van Criekinge.

2021

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis : a prospective, multicenter study in biopsy-naive men
R. Hendriks, M. van der Leest, B. Israel, G. Hannink, A. YantiSetiasti, E. Cornel, C. Hulsbergen-van de Kaa, O. Klaver, J. Sedelaar, W. Van Criekinge, H. de Jong, P. Mulders, E. Crawford, J. Veltman, J. Schalken, J. Barentsz and I. van Oort
(2021) PROSTATE CANCER AND PROSTATIC DISEASES, 24,

2020

The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality
J. Delanghe, M. De Buyzere, S. De Bruyne, W. Van Criekinge and M. Speeckaert
(2020) ANNALS OF ONCOLOGY, 31,

Validation of a 2-gene mRNA urine test for the detection of >= GG2 prostate cancer in an opportunistic screening population
J. Rubio-Briones, A. Borque-Fernando, L. Esteban, J. Mascaros, M. Ramirez-Backhaus, J. Casanova, A. Collado, C. Mir, A. Gomez-Ferrer, A. Wong, F. Aragon, A. Calatrava, J. Lopez-Guerrero, J. Groskopf, J. Schalken, W. Van Criekinge and J. Dominguez-Escrig
(2020) PROSTATE, 80,

Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals
S. Kint, W. Trypsteen, W. De Spiegelaere, E. Malatinková, S. Kinloch-de Loes, T. De Meyer, W. Van Criekinge and L. Vandekerckhove
(2020) CLINICAL EPIGENETICS, 12, 36

A urine based genomic assay to triage patients with hematuria for cystoscopy
K. van Kessel, J. de Jong, A. Ziel-van der Made, H. Roshani, S. Haensel, J. Wolterbeek, E. Boeve, E. Oomens, N. van Casteren, M. Krispin, J. Boormans, E. Steyerberg, W. Van Criekinge and E. Zwarthoff
(2020) JOURNAL OF UROLOGY, 204,

2019

MEXPRESS update 2019
A. Koch, J. Jeschke, W. Van Criekinge, M. van Engeland and T. De Meyer
(2019) NUCLEIC ACIDS RESEARCH, 47,

Clinically significant prostate cancer diagnosed using a urinary molecular biomarker-based risk score : two case reports
P. Minnee, D. Hessels, J. Schalken and W. Van Criekinge
(2019) BMC UROLOGY, 19, 124

Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in African American men
R. Waterhouse, L. Van Neste, K. Moses, C. Barnswell, J. Silberstein, M. Jalkut, R. Tutrone, J. Sylora, R. Anglade, M. Murdock, Z. Shiffman, T. Vandenberg, N. Shah, M. Carter, M. Krispin, J. Groskopf and W. Van Criekinge
(2019) UROLOGY, 128,

Cost-effectiveness of SelectMDx for prostate cancer in four European countries : a comparative modeling study
T. Govers, D. Hessels, V. Vlaeminck-Guillem, B. Schmitz-Draeger, C. Stief, C. Martinez-Ballesteros, M. Ferro, A. Borque-Fernando, J. Rubio-Briones, J. Sedelaarll, W. Van Criekinge and J. Schalken
(2019) PROSTATE CANCER AND PROSTATIC DISEASES, 22,

PROTEOFORMER 2.0 : further developments in the ribosome profiling-assisted proteogenomic hunt for new proteoforms
S. Verbruggen, E. Ndah, W. Van Criekinge, S. Gessulat, B. Kuster, M. Wilhelm, G. Menschaert and P. Van Damme
(2019) MOLECULAR & CELLULAR PROTEOMICS, 18,